Please wait while the formulary information is being retrieved.
ORGOVYX (relugolix)
- advanced form of prostate cancer
120 mg tablet
- 1 tablet (120 mg) by oral route once daily
Default screening record
- 1 tablet (120 mg) by oral route once daily
- 2 tablets (240 mg) by oral route once daily
- 3 tablets (360 mg) by oral route once
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Pregnancy
Severe
Moderate
- None
ORGOVYX (relugolix)
- advanced form of prostate cancer
- Anemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Constipation
- Diarrhea
- Drug-induced hot flash
- Hyperglycemia
- Hypertriglyceridemia
- Musculoskeletal pain
More Frequent
Severe
Less Severe
- None
- Depression
- Gynecomastia
- Hyperhidrosis
- Insomnia
- Libido changes
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Anaphylaxis
- Angioedema
- Cardiac arrhythmia
- Hemorrhage
- Hypersensitivity drug reaction
- Kidney disease with reduction in GFR
- Urticaria
Less Severe
- Urinary tract infection
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Relugolix
Safety and efficacy not established in pediatric patients.
- 1 Day – 18 Years
- Safety and efficacy not established in pediatric patients.
Relugolix
- Severity Level:
D
- Additional Notes: Treatment not indicated in women.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Relugolix
Treatment not indicated in women
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Treatment not indicated in women |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Advanced prostatic carcinoma | |
| C61 | Malignant neoplasm of prostate |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
Formulary Reference Tool